Ca&Bone

[Vitamin D supply and the effect of short term calcium and vitamin D supplementation in postmenopausal women with osteoporosis or osteopenia]

FERENCZ Viktória és munkatársai

AUGUST 20, 2003

Ca&Bone - 2003;6(04)

[INTRODUCTION - The effect of short-term calcium and vitamin D supplementation by a clinical nutriment on bone formation and resorption was studied in postmenopausal women with normal or decreased calcidiol serum levels. PATIENTS AND METHODS - Ninety-one postmenopausal women (age, 60-75 years) were enrolled in the study to investigate the effect of 1120 mg calcium and 208 IU vitamin D in a complex composition (Fortimel®, Nutricia) on bone turnover after 4 weeks of treatment. All women suffered from osteopenia or osteoporosis detected by bone densitometry. Serum parathyroid hormone levels and bone turnover markers (serum β-CrossLaps, osteocalcin and alkaline phosphatase) were determined before and after the treatment. Moreover, calcidiol serum level was also measured at the beginning of the study to assess vitamin D supply. A questionnaire was used to assess gastrointestinal side effects and urinary calcium/creatinine ratio was calculated to estimate the risk of kidney stone development. RESULTS - In the entire patient group the mean serum level of β-CrossLaps was elevated (526.97±29.26 pg/ml) before the study and decreased during the treatment (485.58±28.27 pg/ml, p=0.03).The mean serum level of osteocalcin (28.58±1.37 vs. 27.03±1.36 ng/ml, p=0.025) and serum alkaline phosphatase activity (200.46±8.72 vs. 186.94±11.64 U/l, p=0.033) both decreased.The serum 25-OH vitamin D3 was below 30 ng/ml in 20 patients before the treatment, suggesting vitamin D deficiency.A correlation (r=0.508, p<0.001) between the decrease of bone formation and the decrease of bone resorption was found only in patients with normal serum 25-OH vitamin D3 concentration (>30 ng/ml). However, bone turnover did not decrease in patients with calcidiol deficiency. Urinary calcium/creatinine ratio remained unchanged during the treatment, but two patients suffered from constipation and one of them had diarrhea due to the calcium supplementation. CONCLUSIONS - Calcium and vitamin D supplementation in a complex clinical nutriment proved to be effective in decreasing bone turnover in postmenopausal women with good vitamin D supply, even after a short treatment period of 4 weeks. However, this treatment was ineffective in patients with vitamin D deficiency suggesting the importance of serum calcidiol measurement before calcium supplementation. Calcium in complex with other nutrients such as citrate did not increase the risk of renal stone formation in the short run, and only caused gastrointestinal problems in a tiny fraction of patients.]

COMMENTS

0 comments

Further articles in this publication

Ca&Bone

[Quality of life and osteoporosis]

BÁLINT Géza

Ca&Bone

[FORTHCOMING CONGRESS]

Ca&Bone

[Dear Colleagues and Readers!]

HORVÁTH CSABA

Ca&Bone

[The effects of thyroid hormones on bone]

BAJNOK Éva, LAKATOS Péter

[The effects of thyroid hormones on bone tissue are of fundamental importance.They are required for skeletal development and later for normal bone metabolism.Their action is dose-dependent and also depends on the degree of differentiation of the target tissue. In childhood, thyroid hypofunction manifests itself in growth retardation, whereas hyperfunction will accelerate bone maturation.The exact mechanism of action of thyroid hormones on bone in later years is poorly understood, and their clinical relevance on the risk of bone fracture, the most important complication, is also unclear. In adults with hypothyroidism, bone mineral density (BMD) remains unchanged or even becomes increased, but the risk of fractures is elevated. In hyperthyroidism the bone turnover is increased, which may lead to a decrease in BMD and a higher risk of fracture. However, the results are inconsistent for endogenous subclinical hyperthyroidism, where BMD may also decrease and fractures may occur more frequently.Treatment of hypothyroidism may temporarily result in increased fragility but this phenomenon seems to be only transient. During L-T4 replacement therapy the TSH level should be kept in the normal range, while with suppression, it should be set to the lower end of the normal range. During treatment of hyperthyroidism BMD temporarily increases and the risk of fractures decreases.The most effective way of preventing osteoporosis and bone fractures in all cases is the early recognition and treatment of thyroid diseases.The presence of other osteoporosis risk factors should always be considered. In some cases adjuvant therapy may be necessary to stop bone loss.]

Ca&Bone

[Renal stone formation after parathyroidectomy in patients with primary hyperparathyroidism]

BERCZI Csaba, BALÁZS György, LUKÁCS Géza, TÓTH Csaba

[INTRODUCTION - The incidence of renal stone formation was studied in patients with primary hyperparathyroidism after parathyroidectomy. PATIENTS AND METHODS - Ninety-two patients operated on for hyperparathyroidism were included in the study. In Group 1 the patients (n=44) had kidney stones before parathyroidectomy. Patients with no history of nephrolithiasis (n=48) before the operation were assigned to Group 2. After the operation the occurrence of renal stones was assessed for both groups.The presence of any association between the recurrence of renal stones and various clinical parameters was analysed. RESULTS - The serum concentration of Ca and parathormone decreased to the normal range in both groups after the operation. Stone formation was observed in nine cases in five patients during follow-up. All five patients belonged to Group 1.Thirty-three % of these recurrent stones were diagnosed within the first year and 89% within 5 years. Statistical analysis did not reveal any significant association between recurrent stone formation and gender, age, preoperative serum levels of Ca and parathormone or the histology of parathyroid glands. CONCLUSION - The incidence of recurrent renal stones after successful parathyroidectomy significantly decreased in patients with primary hyperparathyroidism.]

All articles in the issue

Related contents

LAM KID

[The concept of adherence and its significance in osteoporosis]

SZEKERES László

[Today, in relation to the economical aspects of medical therapies, the patterns of patients’ drug taking have come into focus. One of the important indicators is adherence, which consists of four different concepts concerning faithfulness to therapy: acceptance, concordance, persistance and compliance. In chronic diesases, medical therapy without a certain degree of adherence is no more useful than no therapy at all. A number of international clinical studies show that in osteoporosis, the therapy can only lead to a decrease in the number of fracture in case of sufficient adherence.]

Ca&Bone

[Relationship of cardiovascular risk factors and bone status in a large adult population of the Balaton Region]

BUDAY BARBARA, IZSÓNÉ KATZ MELITTA, NAGY ELVIRA, PAPP ZSUZSA, KORÁNYI LÁSZLÓ

[BACKROUND - Numerous international studies have investigated the relationship between bone metabolism and type 2 diabetes mellitus. The results are controversial, there are those proving an increasing effect of diabetes on bone density but we know data that prove the opposite results. Our aim was to investigate the relationship between bone density, obesity and carbohydrate metabolism on a large Hungarian population. PATIENTS AND METHODS - The data from a large population screening (n=6287, mean age 56±13 years, men: n=1561, women: n=4726), carried out in the Balaton Region, Hungary, were analyzed (anthropometry, blood glucose and total cholesterol, blood pressure, calcaneus ultrasound T-score). RESULTS - Analyzing the relationship between type 2 diabetes and osteoporosis/osteopenia, we found, that the prevalence of osteopenia is significantly higher in diabetic women between 50-60 years of age than that of normal glucose tolerance, (50 vs. 36.34%, OR: 1.711, 95% CI: 1.076-2.722, p<0.022), however in different age groups and in males there were no significant differences, similar to the metabolic syndrome which did not influence the prevalence of osteoporosis/osteopenia. In normal weight (male and female) diabetic population over 60 years of age, the frequency of osteoporosis/ ostepenia was much higher, than in the normal weight normal glucose tolerance group, which difference was borderline-significant in the case of osteoporosis (63.63 vs. 26.2%, OR: 2.71, 95% CI: 0.969-7.6, p=0.054), and did not reach it with osteopenia (53.38 vs. 43.31%, p=0.359). In the same age group, within the “all glucose intolerant” and “all normal glucose tolerance” groups the prevalence of osteoporosis/osteopenia did not differ. We found significant correlation between BMI and T score only in women and it was strongest in age group of over 70 years (r=+0.23, p<0.001). CONCLUSION - Our data suggest that the increased bone density often measured in type 2 diabetic patients is actually the consequence of the accompanying obesity, and not of diabetes itself, which is rather a risk factor for bone loss.]

LAM KID

[The role of bone turnover markers in the diagnosis and therapy of osteoporosis]

HONTVÁRI Lívia, KRÁNICZ Ágota

[Osteoporosis is a metabolic bone diseasecharacterised by decreased bone mass andimpaired bone turnover, which leads to anincreased risk of fractures and significantmorbidity and mortality. Its social and pub-lic health impact and the importance of itsearly and accurate diagnosis are indis-putable. The aim of timely and efficienttherapy is to improve bone quality as wellas to prevent the dreaded complications ofbone fractures. In clinical practice, labora-tory diagnosis of biochemical bone mark-ers are particularly important for therapeu-tic monitoring. In this article, reviewing lit-erature data, we discuss bone-specificmarkers from the clinician’s perspective,and highlight their importance in everydayclinical practice. ]

Ca&Bone

[Overcome of bisphosphonate resistance with alphacalcidol: results of a one year, open follow-up study]

GAÁL János, BENDER Tamás, VARGA József, HORVÁTH Irén, KISS Judit, SOMOGYI Péter, SURÁNYI Péter

[INTRODUCTION - A considerable part of osteoporotic patients do not respond satisfactorily to adequate treatment with a bisphosphonate plus supplementation with calcium and conventional vitamin D3. This study intended to determine whether the replacement of vitamin D3 with alphacalcidol results in any BMD increase, i.e. is it possible to overcome resistance to bisphosphonates. PATIENTS AND METHOD - In 76 patients unresponsive to the combination of alendronate and conventional vitamin D3, the latter had been replaced with alphacalcidol (0.5 μg/day), and then the patients were followed up for a year. Clinical and laboratory parameters were recorded at baseline and after one year of treatment; and their changes were analysed by statistical methods. RESULTS - After treatment for one year, Wilcoxon test revealed a small but statistically significant (p<0.001) increase in the BMD values of the forearm (+2.2%) and lumbar vertebrae (+1.4%). At the end of the treatment period, the following, significant changes were observed compared to baseline (median values): serum calcium level increased by 0,06 mmol/l; serum phosphorus level decreased by 0.05 mmol/l, serum alkaline phosphatase activity decreased by 13 U/l, and urinary calcium/creatinine ratio in first-voided morning urine increased by 0.1. Additionally, serum PTH level decreased by 10.7 pg/ml (median). Serum levels of osteocalcin decreased by 0.4 ng/ml, along with the urinary D-Pyr /kreatinine ratio by 0.2 nmol/mmol (median). No significant increase of adverse events occurred. DISCUSSION - As suggested by our results, combination therapy with alendronate and alfacalcidol increases bone density and improves the biochemical markers of bone turnover - without any substantial increase in the incidence of adverse effects.]

LAM KID

[Practical questions regarding the use of teriparatide]

TAKÁCS István

[Teriparatide has become one of the most important drug in the treatment of osteoporosis in Hungary. Although this is not a new drug, a number of questions arise regarding its use in everyday practice. When should we use it as first-line treatment? When should we change the used therapy to teriparatide? What kind of effect can we expect after the start of teriparatide therapy? What are the potential side effects? Financing rules limit, but do not fully control our therapeutic decisions, as these are mostly based on scientific data. In this review, we summarise new and older scientific data regarding teriparatide from practical aspects.]